ORAMED
PHARMACEUTICALS INC.
Hi-Tech
Park 2/5
PO Box
39098
Jerusalem
91390, Israel
March 3,
2010
VIA EDGAR AND
FACSIMILE
Securities
and Exchange Commission
Mail Stop
4720
100 F
Street, N.E.
Washington,
D.C. 20549
Attention: Nandini
Acharya, Esq., Division of Corporation Finance
|
Re:
|
Oramed
Pharmaceuticals Inc.
|
|
Registration
Statement on Form S-1, filed January 11, 2010, as
amended
|
|
|
SEC
File No.
333-164288
|
Dear Ms.
Acharya:
Pursuant
to Rule 461(a) under the Securities Act of 1933, as amended, it is hereby
requested that the effective date of the above-referenced Registration Statement
on Form S-1 of Oramed Pharmaceuticals Inc. (the “Company”) be accelerated and
that the Registration Statement become effective at 4:30 P.M. on March 3, 2010,
or as soon thereafter as possible.
In
connection with the foregoing acceleration request, the Company acknowledges
that:
|
|
w
|
Should
the Securities and Exchange Commission (“Commission”) or its staff, acting
pursuant to delegated authority, declare the Registration Statement
effective, it does not foreclose the Commission from taking any action
with respect to the Registration Statement;
|
|
w
|
The
action of the Commission or its staff, acting pursuant to delegated
authority, in declaring the Registration Statement effective, does not
relieve the Company from its full responsibility for the accuracy and
adequacy of the disclosure in the Registration Statement;
and
|
|
|
w
|
The
Company may not assert the action of the Commission or its staff in
declaring the Registration Statement effective as a defense in any
proceeding initiated by the Commission or any person under the federal
securities laws of the United
States.
|
|
Very
truly yours,
|
|
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
By:
/s/ Yifat
Zommer
|
|
|
Yifat
Zommer
|
|
|
Chief
Financial Officer
|